Loading stock…

Progyny, Inc. (PGNY) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Progyny, Inc.

PGNYMarket cap $2.11BPrice $27.6

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

Progyny designs fertility and family-building benefits that employers add to healthcare plans, covering IVF, egg freezing, and adoption support. Hundreds of top companies use it to cut turnover and attract talent, betting fertility coverage retains employees better than raises do.

In Bastion Portfolios?

52W Return+42%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+18%9

Revenue Forecast

Rev CAGR (1y)+7%5

Rev CAGR (3y)+8%6

Rev CAGR (5y)+7%6

Earnings Forecast

EPS Growth Y+1+228%10

EPS Growth Y+2+10%6

EPS Growth Y+3+9%6

Quality

Margins

EBIT Margin9%4

Net Income Margin6%4

Free Cash Flow Margin14%7

Debt

Net Debt/EBITDA-1.610

Efficiency

ROE16%7

ROA11%9

Earnings Stability55

GEAR+STRONG84

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)118

P/E Ratio (Forward 3y)107

P/BV4.73

EV Multiples

EV/EBITDA Fwd88

EV/EBIT Fwd89

Yield

Free Cash Flow Yield8.4%8

Dividend Yieldna–

Momentum

Short term

1 month return+1%8

3 month return-10%3

YTD return+7%6

Mid term

Price vs 52wHigh83%6

1 year return+34%8

Long term

3 year return-18%2

5 year return-53%1

Risk Shield

Price Risk

Beta0.67

Volatility54%3

Free Cash Flow

Free Cash Flow Margin14%7

Free Cash Flow Yield8.4%8

Quality

ROCE24%9

Earnings Stability55

Net Debt/EBITDA-1.610

02Growth

Is it actually growing, and how fast?

PGNYProgyny

Revenue FY25$1.3B

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+18%9

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+228%10

EPS growth, FY27E+10%6

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 18%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 8%/yr).

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 18%/yr over the last 3 years; forecasts see it cooling to 8%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE34 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return-10%3

YTD return+7%6

MID & LONG-TERM▾SCORE

% of 52-week high83%6

1-year return+34%8

3-year return-18%2

5-year return-53%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 34% over the past year, but 17% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+1%).

WATCH

Returns sit at the market level so far this year (+7%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-18% over three years and -53% over five), behind 80% of the market.

The stock is underperforming over three months (-10%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Progyny, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

PGNYProgyny

Revenue FY25$1.3B

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+18%9

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+228%10

EPS growth, FY27E+10%6

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 18%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 8%/yr).

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 18%/yr over the last 3 years; forecasts see it cooling to 8%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE34 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return-10%3

YTD return+7%6

MID & LONG-TERM▾SCORE

% of 52-week high83%6

1-year return+34%8

3-year return-18%2

5-year return-53%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 34% over the past year, but 17% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+1%).

WATCH

Returns sit at the market level so far this year (+7%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-18% over three years and -53% over five), behind 80% of the market.

The stock is underperforming over three months (-10%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Progyny, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community